ExpreS2ion Biotechnologies - Presentation of Q4 2024

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit your questions for the event.

ExpreS2ion Biotechnologies is expected to release its Q4 2024 results on 6 February 2025. On the same day at 10:00, the company’s and CFO Keith Alexander will present the results and the achievements in an online live presentation. The management presentation will be followed by a Q&A session.

Besides the financial results for the last quarter of 2024, other focus areas of the presentation could be the capital situation after the latest funding round as well as an update on the news flow since the Q3 2024 report. In early December, the Austrian Agency for Health and Food Safety approved the phase I clinical trial application (CTA) for the breast cancer candidate.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 13.11 10 January 2025.